STOCK TITAN

Aurinia (NASDAQ: AUPH) CFO gets stock, options; covers tax bill

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Financial Officer Joseph M. Miller. On February 27, 2026, he received a grant of 95,700 employee stock options with an exercise price of $0.0000 per share and an award of 57,229 shares of common stock at no cost. The options vest one-third after twelve months from the grant date, with the remaining two-thirds vesting in twenty-four equal monthly installments.

Each performance right associated with these awards represents a contingent right to receive one common share, vesting in four tranches as the share price reaches progressively higher targets, each with a one-year retention period. On March 2, 2026, 37,511 common shares at $14.21 per share were withheld as a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving Miller with 576,421 directly held common shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Miller Joseph M

(Last) (First) (Middle)
#140, 14315 -118 AVENUE

(Street)
EDMONTON A0 T5L 4S6

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/27/2026 A 57,229(1) A $0 613,932 D
Common Stock 03/02/2026 F 37,511(2) D $14.21 576,421 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $13.97 02/27/2026 A 95,700 (3) 02/27/2036 Common Stock 95,700 $0 95,700 D
Explanation of Responses:
1. Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
2. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
3. One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Remarks:
/s/ Joseph M. Miller 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Aurinia (AUPH) CFO Joseph M. Miller receive?

Aurinia CFO Joseph M. Miller received 95,700 stock options and 57,229 shares of common stock. The options were granted at a zero exercise price and the stock was awarded at no cost, reflecting a significant equity-based component of his compensation package.

How do Joseph M. Miller’s new Aurinia (AUPH) stock options vest?

One-third of Miller’s stock options vest twelve months from the grant date. The remaining two-thirds vest in twenty-four equal monthly installments, creating a multi-year incentive structure that ties his potential gains to ongoing service and company performance over time.

What are the performance rights mentioned in the Aurinia (AUPH) Form 4 filing?

Each performance right gives a contingent right to receive one Aurinia common share. These performance rights vest in four tranches when the stock reaches progressively higher target prices, with each tranche subject to a one-year retention period following achievement of its price target.

Why were 37,511 Aurinia (AUPH) shares disposed of for Joseph M. Miller?

The 37,511 shares were withheld as a tax-withholding disposition at $14.21 per share. They were used to satisfy tax obligations triggered when restricted stock units vested, rather than representing an open-market sale initiated for portfolio management or liquidity purposes.

How many Aurinia (AUPH) shares does Joseph M. Miller hold after these transactions?

After the March 2, 2026 tax-withholding disposition, Miller directly holds 576,421 Aurinia common shares. This figure reflects his remaining ownership following the withholding of 37,511 shares to cover tax liabilities arising from the vesting of restricted stock units.
Aurinia Pharmace

NASDAQ:AUPH

AUPH Rankings

AUPH Latest News

AUPH Latest SEC Filings

AUPH Stock Data

1.98B
122.50M
Biotechnology
Pharmaceutical Preparations
Link
Canada
EDMONTON